Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.54 |
| ▸ | TEK | Q02763 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | KIT | P10721 | 10/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29933384 | 0.82 | KIT (0.49) | KDRKITDDR1CNR1ABL1 | |
| SCHEMBL29933030 | 0.81 | TAS1R3 (0.48) | KDRKITDDR1CNR1ABL1 | |
| SCHEMBL29933192 | 0.80 | KIT (0.47) | KDRKITDDR1CNR1ABL1 | |
| SCHEMBL29933322 | 0.80 | KIT (0.51) | KITDDR1CNR1ABL1BCR | |
| SCHEMBL29933176 | 0.79 | KIT (0.47) | KITDDR1CNR1ABL1BCR | |
| SCHEMBL29933073 | 0.78 | KIT (0.47) | KITDDR1CNR1 | |
| SCHEMBL29934104 | 0.77 | TAS1R3 (0.44) | KITDDR1CNR1 | |
| SCHEMBL29933931 | 0.76 | KIT (0.46) | LCKKITCNR1MAPK14SRC | |
| SCHEMBL29932958 | 0.76 | KIT (0.43) | LCKTEKKDRKITDDR1 | |
| SCHEMBL24528562 | 0.76 | LCK (0.58) | LCKTEKKDRKITDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | claimed |
| CN-119371371-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2025-01-28 | — | — | CN | claimed |
| CN-115315421-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2022-11-08 | — | — | CN | claimed |
| CN-119371371-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2025-01-28 | — | — | CN | disclosed |
| CN-115315421-B | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| CN-115315421-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2022-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | LCK 194/4885TEK 22/4885KDR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.